Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 4/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21061903 | 1.00 | HRH3 (0.57) | HRH3KCNH2AADATHTR3A | |
| SCHEMBL21061876 | 0.81 | NPC1 (0.45) | HRH3AADAT | |
| SCHEMBL21061875 | 0.81 | NPC1 (0.45) | HRH3AADAT | |
| SCHEMBL21096638 | 0.77 | HRH3 (0.74) | HRH3KCNH2 | |
| SCHEMBL21061798 | 0.77 | HRH3 (0.70) | HRH3KCNH2 | |
| SCHEMBL21206699 | 0.76 | AADAT (0.53) | HRH3KCNH2AADAT | |
| SCHEMBL21061827 | 0.76 | HRH3 (0.54) | HRH3KCNH2AADAT | |
| SCHEMBL9905489 | 0.75 | HRH3 (0.76) | HRH3KCNH2 | |
| SCHEMBL21206528 | 0.75 | HRH3 (0.59) | HRH3KCNH2AADAT | |
| SCHEMBL21154511 | 0.73 | HRH3 (0.62) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3724197-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019116256-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | HPGDS, HPGD, PTGS1 | HRH3 198/4885KCNH2 3363/4885AADAT 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.